Journal
ANNALS OF HEMATOLOGY
Volume 89, Issue 12, Pages 1255-1263Publisher
SPRINGER
DOI: 10.1007/s00277-010-1020-3
Keywords
Aplastic anemia; hnRNP K; Autoantibody; Bone marrow failure
Categories
Funding
- Ministry of Education, Science, Technology, Sports and Culture of Japan [21390291]
- Research Committee for Idiopathic Hematopoietic Disorders
- Ministry of Health, Labor, and Welfare, Japan
- Grants-in-Aid for Scientific Research [22591032, 21390291] Funding Source: KAKEN
Ask authors/readers for more resources
To identify a new diagnostic marker for the immune pathophysiology of aplastic anemia (AA), we screened sera of immune-mediated AA patients for the presence of antibodies (Abs) specific to proteins derived from a leukemia cell line UT-7 using two-dimensional electrophoresis followed by immunoblotting. The target proteins were identified by peptide mass fingerprinting. Heterogeneous nuclear ribonucleoprotein (hnRNP) K was identified as a novel autoantigen. An enzyme-linked immunosorbent assay revealed high titers of anti-hnRNP K Abs in 85 (31%) of 273 patients with AA. Sixty-four patients received antithymocyte globulin and cyclosporine after undergoing screening for anti-hnRNP K Ab, anti-DRS-1 Ab, anti-moesin Ab, and paroxysmal nocturnal hemoglobinuria (PNH)-type cells. Twenty (87%) of 23 patients with the presence of anti-hnRNP K Abs responded to the immunosuppressive therapy (IST), while 19 (46%) of 41 patients without the presence of anti-hnRNP K Abs responded. A multivariate analysis showed only PNH-type cells and anti-hnRNP K Abs to be significant factors for the prediction of a good response to IST. The detection of anti-hnRNP K Abs as well as PNH-type cells may therefore be useful for diagnosing the immune pathophysiology of AA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available